Kajian klinikal Flu di Illinois
7 kajian untuk Flu sedang mencari peserta di lokasi di Illinois.
Bandar di Illinois
Teks kajian rasmi (Bahasa Inggeris)
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- Research Site, Evanston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05624450High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
- Ann Robert H. Lurie Children's Hospital of Chicago, Chicago
Mengambil pesertaFasa 2
Umur 3 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05947071A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
- GSK Investigational Site, Chicago
- GSK Investigational Site, Morton
- GSK Investigational Site, Peoria
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
Umur 65 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT07805707Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
- AMR Chicago- Site Number : 8400005, Oak Brook
Mengambil pesertaFasa 1/2Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07779408Dime La VerDAD: Verify, Debunk, and Disseminate
- University of Chicago, Chicago
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 hingga 99 · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06417762The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- Ann and Robert Lurie's Children Hospital of Chicago, Chicago
Mengambil pesertaSukarelawan sihat dialu-alukan
6 Months – 99 Years · Semua jantina · Dikemas kini 8 Apr 2026 · NCT05832307Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- University of Illinois Health, Chicago
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jul 2024 · NCT02735707Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.